Influence of dietary myoinositol on myocardial vulnerability and norepinephrine release in a diabetic animal model.
In a canine model of diabetes enhanced ventricular vulnerability (VFT) has been associated with reduced myocardial myoinositol and increased release of norepinephrine (NE). To assess the role of the polyol, a dietary supplement of myoinositol was fed for 1 year to a diabetic group. Diabetes was induced with alloxan, 30 mg/kg. Controls (Group 1) were compared with diabetics without (Group 2) and with the inositol supplement (Group 3). After 1 year the animals were anesthetized to assess VFT. Basal heart rate and arterial pressure were comparable. The VFT in Group 1 was 43 +/- 2.6 ma, 26.7 +/- 2.8 ma in Group 2 (P < 0.02) and 39 +/- 3.5 ma in Group 3 (P < 0.02 vs. Group 2). Since the cardiac sympathetic system may promote arrhythmogenesis, the release of NE into the coronary sinus (CS) has been determined. To assess basal NE release serial arterial (A) and (CS) samples were taken at 5 min intervals for 20 min during infusion of 3H-NE. There was no significant difference between the diabetic groups in the level of arterial NE (HPLC). The mean for NEA-CS was higher in Group 2 (-228 +/- 33 pg/ml) compared to normals (-75 +/- 19 P < 0.02). In Group 3 the mean NE in the coronary venous effluent was -33 +/- 9 pg/ml, significantly less than Group 2. Infusion of 3H-NE was attended by significantly higher 3H-NEcs levels in Group 2. While dihydroxyphenylglycol (DHPG) was increased, 3H DHPG was not, suggesting that an impaired uptake mechanism contributed to the increased NEcs.(ABSTRACT TRUNCATED AT 250 WORDS)
al-Adli
N
N
Department of Medicine, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark 07103-2714.
Torres
R
R
Baker
H
H
Patel
J
J
Abdel-Sayed
M
M
Regan
T
T
D000818:Animals; D002304:Cardiac Pacing, Artificial; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism* / Q000503:physiopathology; D004032:Diet; D004285:Dogs; D007294:Inositol / Q000494:pharmacology* / Q000502:physiology*; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000031:analogs & derivatives / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism*; D009638:Norepinephrine / Q000378:metabolism*; D014693:Ventricular Fibrillation / Q000209:etiology*
D007294:Inositol; D008734:Methoxyhydroxyphenylglycol; C010117:3,4-dihydroxyphenylglycol; D009638:Norepinephrine